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Enterohemorrhagic E. coli (EHEC) is an important subset of Shiga toxin–producing (Stx-producing) E. coli 
(STEC), pathogens that have been implicated in outbreaks of food-borne illness and can cause intestinal and 
systemic disease, including severe renal damage. Upon attachment to intestinal epithelium, EHEC generates 
“attaching and effacing” (AE) lesions characterized by intimate attachment and actin rearrangement upon host 
cell binding. Stx produced in the gut transverses the intestinal epithelium, causing vascular damage that leads 
to systemic disease. Models of EHEC infection in conventional mice do not manifest key features of disease, 
such as AE lesions, intestinal damage, and systemic illness. In order to develop an infection model that better 
reflects the pathogenesis of this subset of STEC, we constructed an Stx-producing strain of Citrobacter roden-
tium, a murine AE pathogen that otherwise lacks Stx. Mice infected with Stx-producing C. rodentium developed 
AE lesions on the intestinal epithelium and Stx-dependent intestinal inflammatory damage. Further, the mice 
experienced lethal infection characterized by histopathological and functional kidney damage. The develop-
ment of a murine model that encompasses AE lesion formation and Stx-mediated tissue damage will provide a 
new platform upon which to identify EHEC alterations of host epithelium that contribute to systemic disease.
Introduction
Shiga toxin (Stx) is a potent phage-encoded cytotoxin, and Stx-
producing Escherichia coli (STEC) have been implicated in serious 
outbreaks of food-borne disease. For example, an E. coli serotype 
O104 strain lysogenized with an Stx phage was responsible for a 
recent large outbreak of diarrheal illness with serious and in some 
instances lethal systemic complications (1). Enterohemorrhagic 
E. coli (EHEC) represent a subset of STEC, and EHEC, particularly 
serotype O157:H7, have been responsible for both sporadic cases 
and epidemic outbreaks of diarrheal illness in the United States as 
well as worldwide (2, 3). Human EHEC infection can cause severe 
local disease, such as hemorrhagic colitis, characterized by dam-
age to the intestinal epithelium, acute abdominal pain, and bloody 
diarrhea (4–7). EHEC infection may also result in life-threatening 
systemic disease, most notably hemolytic uremic syndrome (HUS), 
characterized by the triad of hemolytic anemia, thrombocytope-
nia, and renal failure (6, 8). In fact, HUS is the leading cause of 
renal failure in children (9, 10).
A characteristic pathogenic feature of EHEC — one that it shares 
with enteropathogenic E. coli (EPEC), a cause of infantile diarrhea 
in the developing world, and Citrobacter rodentium, a natural murine 
pathogen — is the ability to generate attaching and effacing (AE) 
lesions (2, 11). These histopathological lesions are characterized by 
intimate adherence of the bacterium to the host cell, effacement of 
brush border microvilli, and the formation of filamentous actin–
rich pedestals beneath bound bacteria (ref. 12; for review, see ref. 2). 
The formation of AE lesions requires translocation of effector 
proteins into the mammalian cell via a type III secretion system 
(13, 14). A critical type III effector protein is Tir, which localizes in 
the host plasma membrane and acts as a receptor for the bacterial 
outer membrane protein intimin, promoting intimate adherence 
and filamentous actin assembly beneath bound bacteria (15–19). 
Both Tir and intimin are essential for colonization and virulence in 
several animal models of EHEC and Citrobacter infection (20–25).
Of the three AE pathogens, only EHEC produces Stx, which is 
largely responsible for the extensive tissue damage and systemic 
disease generated by EHEC (6, 26, 27). Given that Stx is encoded by 
lambdoid prophages, its production is often enhanced upon phage 
induction (28–30). Stx traverses the intestinal epithelium and tar-
gets the endothelium, leading to vascular damage, particularly 
in the kidney and CNS, tissues that express high levels of the Stx 
receptor and the glycolipid globotriaosylceramide, or Gb3 (31–33). 
Once inside eukaryotic cells, Stx inhibits protein synthesis by inac-
tivating ribosomes. The action of Stx on endothelial cells leads to 
the induction of proinflammatory cytokines, thrombus formation 
in the vasculature, and renal damage (34–38). Stx1 and Stx2 are 
the two major serotypes of Stx, and EHEC that express exclusively 
Stx2 are associated with a greater risk of HUS (39–41). There are 
several variants of Stx2, of which Stx2c and Stx2dact are particu-
larly important in human disease (42–44). In particular, Stx2dact 
is proteolytically activated in the intestinal mucus and is associ-
ated with STEC that cause toxigenic illness in humans despite the 
fact that they lack the ability to generate AE lesions (45, 46).
Injection of Stx into mice results in the induction of proinflammato-
ry cytokines, vascular damage, hemolysis, and renal damage (47–50), 
but in contrast to piglet and rabbit infection models (23, 51–53), 
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STEC strain originally isolated from ground beef (66). In prelimi-
nary screening of these C. rodentium lysogens, only C. rodentium 
(Φ1720a-02) produced significant amounts of toxin in vitro or 
caused systemic disease in mice (data not shown; see Figure 1). In 
order to facilitate the generation of lysogens of Φ1720a-02, the 
phage was marked with a chloramphenicol resistance cassette (cat, 
CmR) (see Methods). C. rodentium DBS100 (11) (referred to herein 
as C. rodentium) was lysogenized with Φ1720a-02 Rz::cat to create 
C. rodentium DBS770 (Φ1720a-02 Rz::cat), which, for simplicity, we 
herein refer to as C. rodentium (λstx2dact). In addition, a C. rodentium 
lysogen of an Stx-deficient control phage, λstx2dact::kanR, was also 
generated (see Methods).
To test whether C. rodentium (λstx2dact) was able to produce Stx2 
upon in vitro growth, the level of Stx2 was quantified by ELISA. 
Spontaneous prophage induction is predicted to release toxin into 
culture supernatants, so supernatants and bacterial pellets were 
analyzed separately. EDL933, an EHEC O157:H7 strain that har-
bors both stx1 and stx2 (67), produced high levels of Stx2 in both 
the supernatant and pellet (Figure 1). In contrast, TUV93-0, the 
stx1- and stx2-deficient derivative of EDL933 (68), was completely 
unable to produce Stx2. EC1720a, which harbors Φ1720a-01 and 
Φ1720a-02, produced easily detectable levels of Stx2 in both super-
natant and pellet, albeit at levels several orders of magnitude lower 
than those found for EDL933, suggesting that baseline expression 
and/or prophage induction is lower in this strain. Importantly, 
C. rodentium (λstx2dact) produced high levels of Stx2, the vast major-
ity of which was present in the culture supernatant. As predicted, 
C. rodentium (λstx2dact::kanR) did not produce detectable toxin.
Induction of the Stx-producing prophage often promotes 
high-level production of Stx by EHEC strains (28–30), so each 
of the above bacterial strains was treated with mitomycin C to 
induce lysogenic phage. Compared with uninduced samples, 
cultures of EDL933, EC1720a, and C. rodentium (λstx2dact) treated 
with mitomycin C produced several orders of magnitude more 
Stx2, particularly in the supernatant, consistent with lytic induc-
tion of the stx-encoding prophage (Figure 1). Strain TV93-0 
and C. rodentium (λstx2dact::kanR) did not produce any Stx upon 
mitomycin C treatment, as predicted. Notably, the levels of Stx 
produced by C. rodentium (λstx2dact) were comparable to or higher 
than the levels generated by the EHEC strains EC1720a and 
EDL933, suggesting that this strain might produce Stx-mediat-
ed disease upon animal infection.
The sequences of stxA (Stx2d activatable A subunit) and stxB 
(Stx2d activatable B subunit) of Φ1720a-02 were determined, 
and although the inferred amino acid sequences aligned well 
with non-mucus-activatable Stx2d (69), the A subunit contained 
the C-terminal glutamic acid necessary for activation of Stx2dact 
(refs. 46, 58, and Supplemental Figure 1, A and B; supplemen-
tal material available online with this article; doi:10.1172/
JCI62746DS1). Thus, we tested the capacity of the toxin produced 
by C. rodentium (λstx2dact) to be activated in the presence of intes-
tinal mucus. Strains B2F1, which encodes the mucus-activatable 
toxin Stx2dact, and EH250, which encodes the non-activatable 
Stx2d, were used as positive and negative controls, respectively 
(46, 69, 70). Culture supernatants from each strain were incu-
bated with murine intestinal mucus or with buffer alone, and 
the Vero cell cytotoxicity of serially diluted samples was deter-
mined. Toxin activity in culture supernatants from E. coli strain 
B2F1 increased approximately 15-fold upon incubation with 
murine mucus (Table 1). In contrast, the toxin activity of EH250, 
murine oral EHEC infection models do not recapitulate AE lesion 
formation, extensive mucosal colonization, or intestinal damage 
(54–56). For example, in conventional mice, Stx-mediated mortal-
ity occurs only after administration of large numbers of EHEC, 
numbers that diminish in the days following inoculation (55, 56). 
Disruption of the normal flora by antibiotic pretreatment, or its 
complete elimination by rearing of the animals in a germ-free envi-
ronment, sensitizes mice to lethal infection after relatively low-
dose oral inoculation (57–59). However, only STEC that produce 
the mucus-activatable allele Stx2dact consistently cause lethal 
infection of streptomycin-pretreated mice (58, 59). Furthermore, 
EHEC infection of altered-flora mice does not result in well-doc-
umented AE lesions, nor have bacterial genes that promote AE 
lesion formation been demonstrated to be required for intestinal 
colonization or disease (57–61). Indeed, a laboratory E. coli K12 
strain that overproduces Stx2 but lacks Tir, intimin, and the type 
III secretion apparatus is capable of lethal infection of streptomy-
cin-pretreated mice (61).
The AE pathogen Citrobacter rodentium has been used extensively 
as a murine model for EHEC and EPEC colonization (20, 62–65) 
but does not express Stx. To establish an infection model that 
reflects both the characteristic mode of intestinal colonization 
and Stx-mediated disease, we constructed a C. rodentium strain 
lysogenized by an Stx2dact-producing phage. Administration of 
C. rodentium (λstx2dact) to mice by oral gavage recapitulated Tir-
dependent AE lesion formation, as well as important aspects of 
systemic Stx-mediated disease, such as intestinal and renal dam-
age. Thus, C. rodentium (λstx2dact) provides a model for EHEC colo-
nization and toxin-mediated disease in conventional mice.
Results
Cultured C. rodentium (λstx2dact), a C. rodentium strain lysogenized with 
a λ Stx phage, produces mucus-activatable Stx2dact at levels comparable to 
STEC. In order to develop a murine model of Stx-mediated disease 
using C. rodentium, we generated C. rodentium strains expressing 
Stx1 or any of several alleles of Stx2, as well as Stx1/Stx2 hybrids 
(data not shown; see Methods). Two phages, Φ1720a-02 and the 
previously identified Φ1720a-01, were derived from EC1720a, a 
Figure 1
C. rodentium (λstx2dact) produces high levels of Shiga toxin upon pro-
phage induction at levels comparable to EHEC isolates. Stx2 in super-
natants (S) or pellets (P) of untreated or mitomycin C–treated cultures 
of the indicated strains was measured by capture ELISA, and results 
are expressed relative to bacterial number (see Methods). ND, not 
detected. Cr, C. rodentium. Data shown are the averages ± SEM of 
quadruplicate samples. Data show results of 1 experiment representa-
tive of 3 independent experiments.
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end of monitoring, 10 days after infection (Figure 2A). C. rodentium 
(λstx2dact) colonized the feces with similar kinetics, reaching a peak 
of approximately 1010 CFU per gram (Figure 2A).
To test whether mice infected with C. rodentium (λstx2dact) expe-
rience Stx-mediated intestinal disease, we monitored fecal water 
content. As expected, feces from uninfected mice contained 
45%–60% water throughout the course of infection (Figure 2B). 
Feces from mice infected with C. rodentium DBS100 or C. rodentium 
(λstx2dact::kanR) had similar water content through day 4 after infec-
tion but starting at post-infection day 6, a time point at which 
maximal bacterial burden was reached, contained elevated levels of 
water, as previously observed for non-Stx-producing C. rodentium 
(71). In contrast, water content of feces from mice infected with 
C. rodentium (λstx2dact) was significantly elevated (>70%) at 4 days 
after infection (Figure 2B), indicating that the production of Stx 
was associated with an early increase in fecal water content. By 8 days 
after infection, fecal water content declined to normal values, 
which could be due to the putative increasing dehydration and 
concomitant water reabsorption that may occur in these mice dur-
ing later stages of infection (see Figure 2B).
Weight loss is a notable feature in mice after Stx injection 
or infection in mice with an intact commensal flora with high 
doses of STEC (47, 48, 54). We found that mock-infected mice, 
as well as mice infected with C. rodentium DBS100 or C. rodentium 
(λstx2dact::kanR), maintained body weight throughout infection, indi-
cating that infection with C. rodentium strains that do not produce 
Stx were not associated with weight loss (Figure 2C). In contrast, 
mice infected with C. rodentium (λstx2dact) lost >10% of their starting 
weight by 6 days after infection and >20% by 8 days after infection.
Finally, the severe weight loss in mice infected with C. rodentium 
(λstx2dact) corresponded temporally with mortality or severe disease 
warranting euthanasia (Figure 2D). All mock-infected mice or mice 
which does not contain mucus-activatable toxin, increased only 
minimally in the presence of the mucus (Table 1). Toxin activ-
ity in the culture supernatant of C. rodentium (λstx2dact) increased 
approximately 18-fold, comparable to the activity of E. coli B2F1, 
upon incubation with mucus, indicating that the Stx produced by 
λstx2dact is indeed mucus activatable (Table 1).
C. rodentium (λstx2dact) causes lethal infection in mice. To determine 
whether C. rodentium (λstx2dact) would provide an Stx-mediated 
disease model, we infected 5- to 8-week old C57BL/6 mice with 
approximately 1 × 109 CFU of this strain via oral gavage. As con-
trols, the Stx-deficient derivative C. rodentium (λstx2dact::kanR) and 
the parental nonlysogen C. rodentium DBS100 were inoculated in 
parallel. Fecal shedding of C. rodentium DBS100 and C. rodentium 
(λstx2dact::kanR) reached approximately 3 × 109 to 5 × 109 per gram of 
feces at day 6 after infection and remained relatively constant to the 
Table 1
Stx2d from C. rodentium (λstx2dact) is mucus activatable
Strain Fold activation Range n
Cr (λstx2dact) 17.9 ± 5.3A 5.4–31 4
B2F1 15.2 ± 2.9A 11.7–21 3
EH250 1.2 ± 0.1 1.1–1.3 2
Supernatant from C. rodentium (λstx2dact), B2F1 (as a positive control), 
and EH250 (as a negative control) were tested for Vero cell cytotoxicity 
in the presence or absence of mouse intestinal mucus. Shown is the 
average fold increase in cytotoxicity (±SEM) with the addition of mouse 
intestinal mucus compared with supernatants incubated with buffer 
alone. n represents the number of replicates performed for each strain 
tested. Statistical significance was determined using 1-way ANOVA.  
AP < 0.05 compared with the increase in activation of EH250 in the pres-
ence of intestinal mucus.
Figure 2
C. rodentium (λstx2dact) causes lethal infection in mice. (A) Colonization of 5-week-old C57BL/6 mice by C. rodentium (λstx2dact), C. rodentium 
(λstx2dact::kanR), and C. rodentium (DBS100) was determined by viable stool counts. Shown are the average CFU (±SEM) of 5 mice. (B) Fecal 
water content of mock-infected 5-week-old mice or mice infected with C. rodentium (λstx2dact), C. rodentium (λstx2dact::kanR), or C. rodentium 
(DBS100). Shown are the averages (±SEM) of groups of 5 mice. Range of average fecal water content of uninfected mice is represented by the 
vertical bar at 0 days after infection. *P < 0.05 compared with all other groups as determined by 2-way ANOVA followed by Bonferroni post tests. 
(C) Body weight during infection of 8-week-old mice, expressed as percent change from day 0. Shown are the averages (±SEM) of 5 mice per 
group. **P < 0.01, ***P < 0.001 compared with all other groups as determined by 2-way ANOVA followed by Bonferroni post tests. (D) Percent 
survival of groups of five 8-week-old mice that were mock infected or infected with C. rodentium (λstx2dact), C. rodentium (λstx2dact::kanR), or 
C. rodentium (DBS100). For all panels, results are representative of at least 5 independent experiments.
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test were complicated by the fact that this nonquantitative 
assay also detected occult blood in the stool of mice infect-
ed with the non-Stx-producing C. rodentium (λstx2dact::kanR) 
(Supplemental Figure 2).
To assess the presence of AE lesions in mice infected 
with C. rodentium (λstx2dact), we examined colonic tissue 
by transmission electron microscopy (TEM) at 6 days 
after infection. Indeed, intimate bacterial attachment, 
microvillar effacement, and robust actin pedestals were 
produced on the intestinal epithelium of mice infected 
with C. rodentium (λstx2dact), in contrast to the normal 
intestinal architecture observed in mock-infected mice 
(Figure 3A). As predicted from previous work (11), 
Stx was not required for the development of AE lesion 
formation, because mice infected with C. rodentium 
(λstx2dact::kanR) developed distinct AE lesions beneath 
bound bacteria (Figure 3A).
To investigate intestinal disease caused by infection with 
C. rodentium (λstx2dact), the large intestines of mice infect-
ed with C. rodentium (λstx2dact) for 7–10 days were exam-
ined histologically. In accordance with previous studies, 
mice infected with C. rodentium DBS100 or C. rodentium 
(λstx2dact::kanR) showed limited intestinal pathology, with 
only minimal hyperplasia and inflammatory infiltrates 
compared with mock-infected mice (data not shown and 
Figure 3B). (C. rodentium infection typically results in 
colonic hyperplasia only after approximately 14 days of 
infection [refs. 63, 72] and was not observed here). In con-
trast, gross evaluation of intestines from mice infected 
with C. rodentium (λstx2dact) showed severe destruction of 
the intestinal mucosa, colitis, and acute ischemic injury, 
with neutrophil infiltration into the muscularis layer 
and lamina propria and intestinal abscesses (Figure 3B). 
Also present were areas of necrosis and degenerative 
changes in the epithelial cells, with crypt withering 
and an overall loss of goblet cells. These data show that 
C. rodentium (λstx2dact) infection is associated with AE lesion 
formation and severe Stx-mediated intestinal damage.
Stx-mediated systemic induction of proinflammatory 
cytokines during murine infection with C. rodentium (λstx2dact). 
Although Stx is capable of activating complement 
(73–75), serum levels of complement proteins C3 and 
Bb in mice infected with C. rodentium (λstx2dact) were not 
altered, and sC5b-9 was elevated only transiently at 
7 days after infection (data not shown; see Methods). 
Instead, in measuring 23 cytokines in the sera of mice infected with 
C. rodentium (λstx2dact) at 7–10 days after infection (see Methods), 
we found that several proinflammatory cytokines and chemo-
kines commonly associated with disease in humans and ani-
mal models of HUS (47, 48, 50, 76–78) were elevated relative to 
those in mock-infected mice and mice infected with C. rodentium 
(λstx2dact::kanR). Serum levels of the proinflammatory cytokine 
TNF-α were elevated, as were the neutrophil chemoattractants 
IL-17 and KC (Figure 4). Additionally, macrophage/monocyte 
chemoattractants RANTES, MCP-1, and MIP-1β were elevated 
2- to 5-fold in serum from C. rodentium (λstx2dact)–infected mice 
relative to mock-infected mice or mice infected with C. rodentium 
(λstx2dact::kanR) (Figure 4). Thus, induction of the cytokines/che-
mokines was attributable to the production of Stx2dact rather 
than to simple colonization by C. rodentium.
infected with C. rodentium DBS100 or C. rodentium (λstx2dact::kanR) 
survived. In contrast, mortality was observed in mice infected with 
C. rodentium (λstx2dact) starting at day 4 after infection, and (in the 
experiment represented in Figure 2D) no mice survived past day 9. 
Consistent with the previous correlation between weight loss and 
serious systemic disease (47, 48, 54), nearly all (~95%) of mice that 
died or were euthanized had lost >20% body weight at the preced-
ing weight assessment (data not shown).
Stx-mediated intestinal damage during murine infection with C. rodentium 
(λstx2dact). Although EHEC infection of humans is associated with 
hemorrhagic colitis, EHEC and/or STEC infection of streptomycin-
pretreated or gnotobiotic mice does not typically result in obvious 
AE lesion formation or striking intestinal damage (refs. 57, 59, and 
A. Melton-Celsa, unpublished observations). Efforts to document 
Stx-dependent hemorrhagic colitis using a guaiac fecal occult blood 
Figure 3
Stx-mediated intestinal damage during murine infection with C. rodentium 
(λstx2dact). (A) TEM of the proximal large intestine of C57BL/6 mice 6 days after 
mock infection or infection by the indicated strain. White arrowheads indicate the 
presence of actin-rich pedestals. Scale bars: 0.5 μm. (B) H&E-stained large intes-
tinal section of mock-infected mice or mice infected with the designated strain 7 
to 10 days after infection; original magnification, ×100 (top row), ×200 (bottom 
row, left and right panels), ×400 (bottom row, middle panel). Scale bars: 50 μm. 
Black box indicates area of complete crypt loss and abscess formation. Asterisks 
indicate goblet cells that are prominent in normal intestinal tissue and diminished 
in mice infected with C. rodentium (λstx2dact). Arrowhead indicates infiltration of 
inflammatory cells into the mucscularis mucosa and muscularis propria layers.
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C. rodentium (λstx2dact::kanR) was not associated with any significant 
elevation in levels (Figure 5A). Furthermore, the increase in renal 
IL-6 and RANTES was at least in part a reflection of increased 
transcription of the corresponding genes, because RT-PCR anal-
ysis of kidney mRNA revealed elevated levels of Il6 and Rantes 
mRNA relative to mock-infected mice or mice infected with by 
C. rodentium (λstx2dact::kanR) (data not shown).
To evaluate renal pathology associated with the C. rodentium 
(λstx2dact) infection model, kidney sections were taken between 7 
and 10 days after infection from mice infected with C. rodentium 
(λstx2dact) and were stained with H&E and PAS. Although renal 
cytokines were elevated, infection with C. rodentium (λstx2dact) was not 
associated with a striking renal inflammatory response (Figure 5B 
and data not shown), nor was CCR1, a chemokine receptor associ-
ated with renal inflammation (80), elevated in the kidney (data not 
shown and see Methods). Instead, consistent with the observation 
that Stx intoxication of mice results in tubular damage (47–49), 
kidneys of mice infected with C. rodentium (λstx2dact) showed prox-
imal tubule injury that was not evident in the kidneys of mock-
infected mice or mice infected with C. rodentium (λstx2dact::kanR) 
(Figure 5B). Their proximal tubular epithelium was flattened, with 
prominent pyknotic nuclear material, loss of luminal brush border, 
and sloughing of dead cells in the tubular lumen (Figure 5B, arrow-
heads). Mitotic activity, indicating regenerative repopulation of the 
proximal tubules, was also observed in some mice (data not shown).
To assess renal function in mice infected with C. rodentium 
(λstx2dact), we measured blood urea nitrogen (BUN) during the 
phase of terminal illness (7–10 days after infection) (see Methods). 
For each mouse euthanized due to severe disease prior to 10 days 
after infection, 1 mouse each from the mock-infected and C. roden-
tium (λstx2dact::kanR)–infected groups was euthanized, and they 
were analyzed in parallel. The mean BUN of mice infected with 
C. rodentium (λstx2dact) was significantly (P < 0.01) elevated rela-
tive to mock-infected mice, and was also elevated relative to mice 
infected with C. rodentium (λstx2dact::kanR), although the latter com-
parison did not reach statistical significance (Figure 5C).
Renal tubular damage, with both leakage of protein and slough-
ing of cells into the lumen, may result in proteinuria, hematuria, 
and elevated levels of the renal tubule–specific biomarker kidney 
injury molecule-1 (Kim-1) (refs. 81–83 and see Methods). Whereas 
urine of mock-infected mice or mice infected with C. rodentium 
The kidney is a specific target of Stx-mediated damage during murine 
infection with C. rodentium (λstx2dact). Although thrombocytopenia 
and hemolytic anemia are two prominent manifestations of HUS, 
the platelet and red blood cell blood counts of mice infected with 
C. rodentium (λstx2dact) were not significantly elevated relative to 
those of mock-infected mice or mice infected with C. rodentium 
(λstx2dact::kanR) (data not shown; see Methods). Red blood cells were 
morphologically normal, and evidence of thrombotic microangi-
opathy, such as platelet aggregates, excessive clotting, or elevated 
levels of fibrin D-dimers, was not observed (data not shown).
We also histologically evaluated several extraintestinal tissues 
for damage upon intestinal infection by C. rodentium (λstx2dact). The 
lungs and heart of mice infected with C. rodentium (λstx2dact) revealed 
no pathology (Supplemental Figure 3, A and B). Nasal turbinates 
express Gb3 receptors (79) but appeared normal after C. roden-
tium (λstx2dact) infection (Supplemental Figure 3C). Although the 
spleens of mice infected with C. rodentium (λstx2dact) showed reactive 
germinal center formation and germinal center hyperplasia with 
large follicles, mice infected with C. rodentium (λstx2dact::kanR) also 
showed considerable germinal center activity (Supplemental Fig-
ure 3D). Finally, examination of the livers of mice infected with 
C. rodentium (λstx2dact) or C. rodentium (λstx2dact::kanR) revealed foci 
of neutrophilic and lymphocytic inflammation as well as scat-
tered hepatocellular death (Supplemental Figure 3E). This injury 
in mice infected with C. rodentium (λstx2dact) was somewhat more 
severe than in mice infected with C. rodentium (λstx2dact::kanR), con-
sistent with the elevation of serum proinflammatory cytokines. 
Consistent with the lack of thrombocytopenia, we found no plate-
let aggregates in any of the tissues (data not shown).
Kidney damage is a hallmark of HUS, and Stx causes renal 
pathology in mice after direct injection or upon absorption from 
intestinal STEC (47, 48, 54, 59). Renal cytokines and chemokines 
are elevated in murine models of Stx intoxication, so we measured 
cytokine and chemokine levels in the kidneys of mice infected with 
C. rodentium (λstx2dact) at 7–10 days after infection. Although the lev-
els of the cytokines IL-6 and G-CSF varied considerably from mouse 
to mouse, they were significantly increased in the kidneys of mice 
infected with C. rodentium (λstx2dact) compared with mock-infected 
controls, as were the chemokines RANTES and KC (Figure 5A). 
In all cases, the increase in cytokine/chemokine levels was 
dependent on the production of Stx2dact, because infection by 
Figure 4
Stx-mediated systemic induction of proinflam-
matory cytokines during murine infection with 
C. rodentium (λstx2dact). The concentrations 
of TNF-α, KC, MIP-1β, IL-17, RANTES, and 
MCP-1 in serum at 7–10 days after infec-
tion in mock-infected mice or mice infected 
with the indicated strain were determined by 
Luminex (see Methods). Data are pooled from 
2 independent experiments, each using 3- to 
8-week-old female mice and 5–10 mice per 
group. **P < 0.01, ***P < 0.001, 1-way ANOVA 
and Tukey’s multiple comparison tests.
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Stx2dact are capable of causing disease in humans (and mice) in 
the absence of AE lesion formation (45, 58, 59). To test whether 
murine infection with C. rodentium (λstx2dact) provided a disease 
model that was dependent on AE lesion formation, we determined 
whether a C. rodentium (λstx2dact) defective for Tir production was 
also defective for colonization and disease. Whereas C. rodentium 
(λstx2dact) and C. rodentium (λstx2dact::kanR) were capable of generat-
ing actin pedestals indistinguishable from those formed by wild-
type C. rodentium DBS100 on monolayers of mouse embryonic 
fibroblasts (MEFs), C. rodentium (λstx2dact)Δtir was impaired in cell 
binding and unable to form pedestals (data not shown). Pedes-
tal formation was restored to this strain by pTir (pEM129), a Tir-
expressing plasmid (data not shown; see Supplemental Table 2 
and Methods). To confirm that Tir was also required for AE lesion 
formation during infection, we compared the intestinal epithelia 
of mice infected with C. rodentium (λstx2dact)Δtir and the paren-
(λstx2dact::kanR) contained no or only trace levels of protein (protein 
index of 0–0.5 indicating <30 mg/dl), urine of mice infected with 
C. rodentium (λstx2dact) contained significantly elevated protein indi-
ces as early as 2 days after infection (Figure 5D). Between 4 and 
7 days after infection, average urine protein indices of the colori-
metric assay were as high 1 to 1.5, corresponding to approximately 
30–100 mg/dl. Hematuria, also assessed using a colorimetric assay, 
was moderately elevated on days 7 and 8 after infection. Finally, the 
marker for tubular damage Kim-1 was also elevated late in infection 
compared with mock-infected mice or mice infected with C. rodentium 
(λstx2dact::kanR). These results indicate that the tubular damage sus-
tained during infection by C. rodentium (λstx2dact) reflected by his-
tological analysis in fact results in functional renal compromise.
Tir is required for colonization and disease in the C. rodentium (λstx2dact) 
infection model. The ability to generate of AE lesions is a well-estab-
lished virulence attribute of EHEC, but STEC strains that produce 
Figure 5
Stx-mediated renal damage during murine infection with C. rodentium (λstx2dact). (A) Renal cytokines in mock-infected mice or mice infected with 
the indicated strain. Data are pooled from 3 independent experiments. *P < 0.05, **P < 0.01. (B) Micrographs (original magnification, ×600) of 
H&E-stained kidney sections from mock-infected mice or the indicated infected mice infected at 7–10 days after infection. Arrowheads indicate 
attenuation and sloughing of epithelial cells within the proximal tubules. Scale bars: 50 μm. (C) BUN of 8-week-old mice, each represented as a 
single data point, infected with indicated strain or mock infected at day of necropsy (7–10 days after infection). Shown is the pool of 4 independent 
experiments using 5 mice per group. **P < 0.01. (D) Proteinuria in mock-infected mice or the indicated infected mice. Data shown are average 
protein indices ± SEM of 5 mice per group. The range of protein measured was 0–500 mg/dl, with 0 indicating undetectable protein, 0.5 indicating 
trace, 1.0 indicating ~30 mg/dl, 2.0 indicating ~100 mg/dl, and 3.0 indicating ~500 mg/dl. Shown is a representative of 5 independent experiments. 
*P < 0.05, **P < 0.01 compared with C. rodentium (λstx2dact::kanR). Hematuria in mock-infected mice or the indicated infected mice infected. Shown 
are the averages (±SEM) of groups of 10 mice. ***P < 0.001 compared with the other groups. Urine Kim-1 concentration in mock-infected mice or 
the indicated infected mice. Shown are the averages (±SEM) of groups of 3–6 mice. **P < 0.01 compared with the other groups.
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peak bacterial burdens reaching almost 1010 per gram of stool 
(Figure 6A). Notably, the kinetics of colonization by C. rodentium 
(λstx2dact)Δtir/pTir were somewhat delayed relative to C. rodentium 
(λstx2dact), consistent with previous reports that plasmid comple-
mentation of a C. rodentium tir mutant is incomplete (20, 84).
The defect of C. rodentium (λstx2dact)Δtir in intestinal colonization 
was reflected in all aspects of Stx-mediated disease. Histological 
analyses of the intestines of mice infected with C. rodentium (λstx2dact)
Δtir were indistinguishable from those of mock-infected mice, 
in contrast to those of mice infected with C. rodentium (λstx2dact)
Δtir/pTir, which showed areas of necrosis, inflammatory infil-
trates, and the loss of goblet cells (Figure 6D). Renal damage was 
associated only with infection by C. rodentium (λstx2dact)Δtir/pTir, 
not with the Tir-deficient mutant (Figure 6E). These histologi-
cal assessments of disease correlated with weight loss, because 
mice infected with C. rodentium (λstx2dact)Δtir maintained weight 
throughout infection (Figure 6B). In contrast, mice infected with 
C. rodentium (λstx2dact)Δtir/pTir lost on average 18% body weight by 
15 days after infection. The kinetics of weight loss by mice infected 
with the Tir-complemented strain, similar to the kinetics of colo-
tal strain C. rodentium (λstx2dact) by TEM at 6 days after infection. 
Whereas infection by C. rodentium (λstx2dact) resulted in effacement 
of the intestinal brush-border microvilli and the formation of 
robust pedestals (Figure 3A), infection by C. rodentium (λstx2dact)Δtir 
left the epithelial cytoskeletal architecture indistinguishable from 
that of mock-infected controls. When tir was introduced in trans 
on pTir, the intestines of mice infected with C. rodentium (λstx2dact)
Δtir/pTir showed many bound bacteria elevated on actin pedestals 
(Figure 3B) with concomitant destruction of microvilli, indicating 
that, as expected, Tir is required for AE lesion formation.
The lack of mucosal attachment by C. rodentium (λstx2dact)Δtir 
revealed by TEM reflected a significant colonization defect when 
assessed quantitatively, because mice infected with C. rodentium 
(λstx2dact)Δtir had vastly fewer fecal bacteria than mice infected with 
C. rodentium (λstx2dact) (Figure 6A). At 3 days after infection, fecal 
counts of mice infected with C. rodentium (λstx2dact)Δtir were approxi-
mately 3 orders of magnitude lower than those of mice infected 
with C. rodentium (λstx2dact), and this difference grew to approxi-
mately 7 orders of magnitude 4 days later. In contrast, C. rodentium 
(λstx2dact)Δtir/pTir was capable of efficiently colonizing mice, with 
Figure 6
Tir is required for colonization and disease upon C. rodentium (λstx2dact) infection of mice. (A) Colonization of 8-week-old C57BL/6 mice that were 
mock infected mice or infected with the indicated strain was determined by plating stool for viable counts. Shown are the averages CFU (±SEM) 
of 5 mice. Data are representative of 5 independent experiments. Statistical significance was determined using 2-way ANOVA and Bonferroni 
post tests and indicates that C. rodentium (λstx2dact)Δtir colonized mice significantly (*P < 0.05) less efficiently than C. rodentium (λstx2dact) and 
C. rodentium (λstx2dact)Δtir/pTir). (B) Body weight during infection of 8-week-old mice is expressed as percent change from day 0. Shown are the 
averages (±SEM) of 5 mice per group. Data are representative of 5 independent experiments. (C) Percent survival of mock-infected 8-week-old 
mice or mice infected with C. rodentium (λstx2dact), C. rodentium (λstx2dact)Δtir, or C. rodentium (λstx2dact)Δtir/pTir. Groups of 5 mice were analyzed. 
Data are representative of 5 independent experiments. (D) H&E-stained large intestinal sections of mock-infected mice or mice infected with the 
indicated strain. Scale bars: 50 μm. Asterisks indicate goblet cells that are prominent in normal intestinal tissue. Arrowhead indicates infiltration 
of inflammatory cells into the mucscularis mucosa and muscularis propria layers. (E) H&E-stained micrograph (original magnification, ×600) of 
kidney sections from mock-infected mice or mice infected with the indicated strain. Arrowhead indicates attenuation and sloughing of epithelial 
cells within the proximal tubules. Scale bars: 50 μm.
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demonstrated elevated BUN, proteinuria, hematuria, and urinary 
Kim-1, a marker of tubular damage, consistent with other murine 
models of HUS (47, 48, 54, 57, 59).
Several manifestations of murine Stx-mediated disease and 
human HUS are absent in the C. rodentium (λstx2dact) murine model. 
For example, neurological damage is associated with HUS, and 
cerebral hemorrhage and edema have been reported in EHEC-
infected, streptomycin-pretreated mice (97, 98). Although mice 
infected with C. rodentium (λstx2dact) occasionally displayed tremors 
and seizures, we did not observe consistent pathological changes 
in the nasal turbinates, a region of the CNS rich in the Stx receptor 
(79). In addition, contrary to what has been observed in human 
disease (6, 8) and Stx administration models (47–49, 88, 99–101), 
mice infected with C. rodentium (λstx2dact) did not display renal 
platelet aggregation, red cell congestion, or fibrin deposition and 
did not show evidence of thrombocytopenia or anemia. Given the 
hypothesis that erythrocytes are ruptured upon passage through 
damaged renal glomeruli (102), it is possible that the lack of glo-
merulonephritis in our model contributes to the lack of observ-
able anemia. We also found no hematological evidence of throm-
botic disease, such as prolonged clotting time or fibrin D-dimer 
formation. Following systemic administration of Stx, mice that are 
deficient in ADAMTS13, a protease that cleaves the hemostatic 
von Willebrand factor, demonstrate wide strain-specific variation 
in the degree of microvascular thrombosis, thrombocytopenia, 
and hemolytic anemia (88, 101). It is possible that infection by 
C. rodentium (λstx2dact) might trigger more overt microangiopathy 
and thus more closely resemble human HUS, in murine strains 
different from the C57BL/6 strain utilized here.
Given that a central goal of this study was to test whether C. roden-
tium (λstx2dact) could recapitulate EHEC toxin–mediated disease, an 
important finding was the requirement for Tir in promoting Stx-
mediated disease in this model. Colonization by a Tir-deficient 
derivative of C. rodentium (λstx2dact) was many orders of magnitude 
lower than colonization by the parental strain. A Tir-encoding plas-
mid complemented the mutant for the ability to colonize mice and 
cause disease. The kinetics of colonization, weight loss, and death 
were somewhat slower than with C. rodentium (λstx2dact), suggesting 
that, as observed in previous studies (20, 84), plasmid-based com-
plementation of a Tir-deficient C. rodentium mutant may result in 
only partial restoration of the wild-type phenotype.
Interestingly, in spite of the reports that the Stx receptor Gb3 
is expressed on cells in the distal colon of the mouse (32, 103), 
the streptomycin pretreatment and gnotobiotic mouse models 
of EHEC infection do not typically result in obvious intestinal 
damage (refs. 57, 59, and A. Melton-Celsa, unpublished observa-
tions). Mild inflammatory cell infiltration, goblet cell depletion, 
and intestinal epithelial necrosis have been reported in a few stud-
ies (97, 104–106). In contrast, we found here dramatic intestinal 
damage in mice infected with C. rodentium (λstx2dact); indeed, these 
pathological changes were similar to those commonly observed in 
human infection by EHEC, which in some cases can mimic inflam-
matory bowel disease or ischemic colitis (107–110). It is tempting 
to speculate that AE lesion formation, a prominent feature of this 
murine infection model, is critical to facilitating Stx-mediated 
intestinal epithelial damage. The development of a murine model 
that encompasses both AE lesion formation and severe Stx-medi-
ated tissue damage provides an opportunity to more fully explore 
the relationship between the pathogen-induced alteration in host 
cytoskeletal structure and subsequent local and systemic disease.
nization, were delayed several days relative to mice infected with 
C. rodentium (λstx2dact), but once average weight began to decrease at 
approximately 10 days post-infection, it declined steadily (Figure 6B). 
Finally, whereas infection by C. rodentium (λstx2dact)Δtir caused no 
mortality, infection by C. rodentium (λstx2dact)Δtir/pTir, like C. roden-
tium (λstx2dact), was uniformly fatal, with the predicted temporal 
delay (Figure 6C). Thus, Tir is an essential virulence factor during 
lethal infection by C. rodentium (λstx2dact).
Discussion
STEC have been implicated in serious outbreaks of diarrheal dis-
ease and systemic damage, including a European outbreak due to 
a serotype O104 STEC strain (1). An important subclass of STEC is 
EHEC, which triggers the formation of AE lesions on the intestinal 
mucosa. Some rabbit and piglet models manifest both AE lesion 
formation and Stx-mediated disease (21, 23, 52, 53, 85), but no 
such model has yet been developed in conventional mice. We show 
here that C. rodentium lysogenized with λStx2dact, which produces 
a mucus-activatable Stx previously associated with severe disease in 
mice (59–61), provides a model that features prototypic AE lesions 
during intestinal colonization and Stx-mediated weight loss and 
death, recapitulating renal dysfunction observed in human HUS 
and murine toxin injection models (4, 54).
Systemic Stx-mediated disease in humans is associated with the 
induction of inflammatory cytokines (77, 86), and patients with 
a preponderance of proinflammatory cytokines often have more 
severe disease (87, 88). Indeed, one model of Stx-mediated disease 
in mice requires the co-administration of LPS and Stx (50). Several 
means by which inflammatory cytokines may promote systemic 
disease have been proposed, including induction of the Gb3 glyco-
lipid Stx receptor on host cells (89–91), alteration of fibrinolysis and 
anticoagulation, or recruitment of inflammatory cells into dam-
aged tissues (77). In response to Stx, cultured monocytes secrete 
TNF-α and IL-6 (90, 92, 93), and we found that these cytokines were 
elevated in the serum or kidneys of mice infected with C. rodentium 
(λstx2dact). This response was dependent on Stx production, because 
neither TNF-α nor IL-6 was elevated in mice infected with C. roden-
tium (λstx2dact::kanR). MCP-1 and KC were also elevated in C. roden-
tium (λstx2dact)–infected mice in an Stx-dependent manner. Notably, 
MCP-1 and IL-8, a functional human analog of KC, are found at 
elevated levels in the urine of children with HUS (94).
Renal damage is central to human HUS (9), and the induction of 
kidney cytokines in the C. rodentium (λstx2dact) model was accompa-
nied by renal compromise. Glomerulonephritis is a prominent fea-
ture of human HUS, a manifestation that correlates with the rela-
tive abundance of Gb3 receptors on glomerular endothelium (95). 
In contrast, Gb3 is enriched in the renal tubules in mice (49), and 
the tubular damage we observed in infected mice likely reflects this 
localization. Consistent with this hypothesis, tubular damage is 
also typically observed in EHEC-infected germ-free or streptomy-
cin-treated mice (49, 57–59). Elevated serum creatinine, an indica-
tor of renal dysfunction, has been observed in some other murine 
models for Stx-mediated disease (47, 48, 59), but we found that 
serum creatinine was not significantly elevated in mice infected 
with C. rodentium (λstx2dact) (E. Mallick, unpublished observations). 
A possible explanation is that elevated serum creatinine is a late 
marker of renal injury (82) and affected by many non-renal factors 
(81, 96). In fact, the renal histopathological findings were reflected 
in other measures of functional compromise, because mice infect-
ed with C. rodentium (λstx2dact), but not C. rodentium (λstx2dact::kanR), 
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upstream of the Rz gene was amplified from EC1720a genomic DNA using 
primers F-425 and R-426, flanked by SphI and BamHI sites. A 692-bp frag-
ment containing sequence downstream of the Rz gene was amplified by 
PCR using primers F-259 and R-427 with BamHI and SacI sites. A 900-bp 
cat cassette was then amplified from pBR328 with flanking BamHI sites 
using primers F-265 and R-266. A tertiary PCR reaction was done using 
the three PCR fragments with primers F-425 and R-427. This tertiary PCR 
fragment was then inserted between the SphI and SacI sites of pUC to cre-
ate pBJK5. This plasmid was digested with SphI and SacI to release a 2.3-kb 
fragment containing the cat cassette flanked by regions of the Rz gene. This 
fragment was electroporated into arabinose-induced EC1720a containing 
the lambda red recombinase plasmid pKD46. The culture was recovered 
in 1 ml SOC for 1.5 hours at 37°C and then plated on LB plates supple-
mented with chloramphenicol to select for recombinants. Recombinants 
were screened by PCR using primer pairs F-425/R-427 and F-265/R-266.
Creation of an stx deletion within EC1720aΔRz::cat. Chimeric PCR was used to 
produce a fragment containing the KmR cassette within an in-frame deletion 
of stxAB. Three PCR reactions were done as follows: (a) template pUC18K 
with primers 2dH1/2dH2, (b) template EC1720a genomic DNA with prim-
ers F-498/R-2dH1AP, and (c) template EC1720a genomic DNA with primers 
F-2dH2AP and R-499. A tertiary PCR was then done using these three PCR 
reactions as templates, and the resulting PCR product was then electropor-
ated into EC1720aΔRz::cat containing the lambda red recombinase plasmid 
pKD46 and induced to recombine. Recombinants were selected on LB plates 
supplemented with chloramphenicol and kanamycin and then screened 
by PCR using the following primer pairs: F-498/R-499, F-2dH1/R-2dH2, 
F-316/R-2dH2, F-316/R-398, and F-2dH1/R-398. The loss of pKD46 from 
the resulting strain, EC1720aΔstx2dactAB::kan ΔRz::cat, was confirmed by 
plating the strain on both kanamycin and ampicillin.
Isolation of Φ1720aΔRz::cat and Φ1720aΔstx2d::kan ΔRz::cat. Recombinant 
Stx bacteriophages Φ1720aΔRz::cat and Φ1720aΔRz::cat Δstx2dactAB::kan were 
isolated from the newly modified genetically manipulated EHEC strains 
JB-13-06 and JB-13-28 (Supplemental Table 1), respectively, as previously 
described (66, 70). Briefly, EHEC isolates were treated with mitomycin C 
(0.5 μg/ml) to induce the bacteriophage lytic cycle and production of phage. 
The cells were treated with 0.5 ml chloroform per 3.0 ml broth culture and 
were filtered through a 0.45-μm-pore-size filter to ensure a cell-free lysate.
Construction of C. rodentium (λstx2dact) and C. rodentium (λstx2dact::kanR). 
The genetically engineered Stx2dact bacteriophages Φ1720a-02ΔRz::cat, 
which has a chloramphenicol resistance cassette inserted into Rz, and 
Φ1720a-02ΔRz::cat Δstx2d::kan, which has a chloramphenicol resistance 
cassette inserted into Rz and a kanamycin resistance cassette inserted 
into Stx2dactAB, were isolated from genetically modified STEC strains 
EC1720aΔRz::cat and EC1720aΔRz::cat Δstx2d::kan, respectively. C. roden-
tium DBS100 (11) was provided with cell surface receptor for bacteriophage 
Stx2d by transformation of plasmid pTROY9, which contains the E. coli 
lamB gene and a tetracycline resistance marker (116, 117). The lambda 
phage receptor was put into DBS100, creating DBS100/pTroy9, and 
induced by growing overnight at 37°C in lambda broth with 0.2% maltose 
and 10 mM MgSO4. This strain was then lysogenized with the antibiotic-
marked bacteriophages as described previously (118), resulting in DBS770 
[C. rodentium (λstx2dact)] or DBS771 [C. rodentium (λstx2dact::kanR)].
Generation of C. rodentium (λstx2dact)Δtir. The C. rodentium (λstx2dact) tir dele-
tion mutant was made as previously described (119) using a slightly modi-
fied version of the 1-step PCR-based gene activation protocol (120).
Construction of a plasmid expressing C. rodentium Tir. Plasmid DNA was 
isolated using the QIAGEN Miniprep procedure. Oligonucleotides were 
from Invitrogen. The C. rodentium complementation vector, pEM129 
(pTir), was created using a modified version of pMB46, pEM123, contain-
ing the additional unique restriction sites MluI and SacII between KpnI 
Methods
Plasmids, bacterial strains, and growth conditions. Bacterial strains and plasmids 
used in this study are listed in Supplemental Tables 1 and 2. All bacteria 
were cultured in Luria-Bertani broth (LB) (Miller) at 37°C, unless other-
wise stated. Antibiotics were used at the following concentrations: kanamy-
cin (25 μg/ml), zeocin (75 μg/ml), and chloramphenicol (10 μg/ml).
Sequencing of Φ1720a-02 from Gobius EC1720. Sequencing of the newly 
identified Φ1720a-02 from EC1720a, a strain originally isolated from 
retail ground beef (66) (provided by Kari Gobius, Food Science Australia, 
Tingalpa, Queensland, Australia) was performed using the panhandle PCR 
technique as previously described (111, 112). The adaptor sequences used 
were F-Adaptor 1 (Supplemental Table 3) and R-Adaptor 2 (Supplemental 
Table 3). Primers F-AP1 and R-AP2 (Supplemental Table 3) were used for 
the PCR reaction and sequencing of the PCR reaction, respectively. Reac-
tions for restriction digests and ligation of adaptors to genomic Φ1720a-02 
DNA were as follows: 1 μg genomic Φ1720a-02 DNA, 10 pmol F-Adapter 
1, 10 pmol R-Adapter 2, 10 U blunt-end restriction enzyme (EcoRV, PvuII, 
RsaI, SspI, XmnI, DraI, HincII, HpaI, ScaI), 2.5 U T4 DNA ligase, 2 μl 
20 mM ATP, 4 μl of ×10 One-Phor-All buffer PLUS (Amersham), and up 
to 20 μl water. Reactions were then incubated at 20°C for 16 hours. Next, 
enzymes were deactivated by heating at 68°C for 10 minutes, and reac-
tions were ethanol-precipitated and resuspended in 50 μl sterile water. The 
panhandle PCR reaction was then performed using 1 μl of the ethanol pre-
cipitated template DNA, 2 μl Taq 10× reaction buffer containing 20 mM 
MgCl2, 1 μl 10 mM dNTP mix, 10 pmol F-AP1 primer, 10 pmol gene-spe-
cific primer, 1 U Taq polymerase, and up to 20 μl water. The PCR cycle 
parameters were as follows: (a) 95°C for 1 minute, (b) 95°C for 30 seconds, 
(c) 68°C for 7 minutes; steps b and c were repeated 25 times. PCR reactions 
were then cleaned up using a QIAGEN spin kit and sequenced at the Tufts 
Core Sequencing Facility.
To confirm the nucleotide and protein sequences of StxA (Stx2d acti-
vatable A subunit) and StxB (Stx2d activatable B subunit) from the newly 
identified Φ1720a-02 (λstx2dact), fragments of both genes, the predicted 
promoter region, and the region upstream of stxA were amplified by PCR 
and TA cloned into JM109 high efficiency competent cells (Promega). The 
following primers (see Supplemental Table 3 for sequences) were used to 
clone each fragment: F-Oli218+R-Oli219 (593 bp), F-Oli224+R-Oli210 
(1.490 kb), R-Oli220+F-Oli221 (1.647 kb), F-Oli222+R-Oli220 (~2 kb), 
R-Oli223+F-Oli222 (1.159 kb), F-Oli224+R-Oli223 (1.3 kb), F-Oli221+R-
Oli210 (918 bp), F-Oli224+R-Oli219 (1.2 kb), R-Oli219+F-Oli226 (~2.1 kb), 
and F-Oli228+R-Oli219 (~2 kb). The clones were screened by colony PCR 
and restriction digestion. Correct clones were sequenced at the Tufts 
Core Sequencing Facility. Fragments were aligned using BioEdit software 
(http://www.mbio.ncsu.edu/bioedit/bioedit.html) and/or MacVector. 
Nucleotide sequences of stxA (Stx2d activatable A subunit) and stxB (Stx2d 
activatable B subunit) were submitted to GenBank and were assigned the 
following accession numbers: JN194203 and JN194204.
Alignment of Φ1720a-02 StxA and StxB with other Stxs. The predicted amino 
acid sequence of the A and B subunits of the Φ1720a-02 from C. rodentium 
(λstx2dact) were aligned with the A and B subunits of Stx2 from EDL933 
(GenBank X078655), Stx2c from E32511 (GenBank M59432), Stx2d from 
EH250 (GenBank AF043627), Stx2dact (formerly called Stx2vhb) from 
B2F1 (GenBank AF479829), and Stx2e from S1191 (GenBank M21534). 
The sequences were aligned using the Align Plus 5 program, version 5.03 
(Scientific & Educational Software) following the global-ref alignment 
procedure (113) and the scoring matrix BLOSUM 62 (114).
Antibiotic marking of Φ1720a-02. To create an antibiotic-marked Stx2-
expressing Φ1720a-02 bacteriophage, a chloramphenicol resistance marker 
(cat, CmR) was inserted into the nonessential gene Rz (115) using lambda 
red recombination. Briefly, a 707-bp fragment containing sequence 
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approximately 5 × 109 of overnight culture of C. rodentium in 100 μl PBS, an 
inoculum that minimizes the potential variability in colonization kinetics 
(119). Inoculum concentrations were confirmed by serial dilution plating. 
C. rodentium fecal shedding was determined by serial dilution plating of 
fecal slurries (10% w/v in PBS) on MacConkey agar with selection for kana-
mycin, chloramphenicol, or kanamycin and chloramphenicol, as appropri-
ate. When complemented strains containing antibiotics were used, feces 
were plated on plates containing both antibiotics. Previously we tested the 
rate of plasmid loss by plating on only one antibiotic and determined that 
it was minimal. Fecal water content was evaluated as previously described 
(71). Water content in stool was expressed as the percentage of wet weight 
minus dry weight divided by wet weight. Fecal occult blood was assessed by 
Sure-Vue Fecal Occult Blood Test (Fisher Healthcare). Fecal occult scores 
were as follows: 0, no occult blood; 0.5, trace amounts of fecal occult blood; 
1, presence of fecal occult blood. Body weights were monitored daily, and 
mice were euthanized if they lost >20% of their body weight. Some mice 
became moribund or died prior to the scheduled necropsy date, and these 
mice were necropsied early. Mouse urinalysis (for proteinuria and hematu-
ria) was performed by collecting urine into a 1.5-ml Eppendorf tube. The 
urine in the tube was thoroughly mixed, and a 5-μl aliquot was pipetted 
onto a Chemstrip 4MD urinalysis test strip (Roche Diagnostics). After 
60 seconds, the color change on the strip was compared to a supplied color 
scale. The range of protein measured was 0–500 mg/dl, with 0 indicating 
undetectable protein, 0.5 indicating trace, 1.0 indicating approximately 
30 mg/dl, 2.0 indicating ~100 mg/dl, and 3.0 indicating ~500 mg/dl. The 
range of hematuria measured was 0–250 erythrocytes/μl, with the scale 
of 0 indicating undetectable hematuria, 10 indicating trace hematuria, 50 
indicating ~50 erythrocytes/μl, and 250 indicating ~250 erythrocytes/μl. 
The amount of Kim-1 in mouse urine was measured using a Kim-1 ELISA 
kit (Adipo Bioscience) according to manufacturer’s protocols. All experi-
mental groups contained at least 5 mice.
Tissue collection and histology. At necropsy, distal colon (~0.5 cm) and one 
kidney were snap frozen in liquid nitrogen and stored at –80°C until RNA or 
protein isolation. Remaining colon, cecum, longitudinally divided kidneys, 
spleen, heart, lung, liver, and nasal turbinates were fixed in 10% buffered 
formalin, dehydrated, and embedded in paraffin. Five-micrometer tissue 
sections were cut and stained with H&E and/or PAS. For CCR1 staining 
of renal tissues by immunofluorescence, sections were stained with rab-
bit anti-mouse CCR1 primary antibody (ProSci Inc.) followed by staining 
with secondary goat anti-rabbit conjugated Alexa488 (Invitrogen). For 
immunohistochemistry, sections were stained with rabbit anti-mouse CCR1 
primary antibody (ProSci Inc.) followed by the Envision+ Dual link system 
HRP (Dako). Tissue sections were evaluated and scored in a blinded manner.
Tissue protein isolation and cytokine analysis. Tissues were homogenized and 
protein was extracted using the Bio-Plex Cell Lysis Kit (Bio-Rad) following 
the manufacturer’s instructions. Briefly, 200–500 μl lysis solution was added 
to sample. Sample was ground on ice using disposable Kontes tubes and dis-
posable pestle and frozen at –80°C. Sample was then thawed and sonicated 
(duty cycle 40, output 6, pulse 18 times). Sample was then centrifuged at 
4,500 g for 20 minutes at 4°C. Protein concentration of the sample was deter-
mined by BCA assay (Thermo Scientific), and protein concentration was 
adjusted to 2 μg/ml with lysing solution. Cytokine analysis was performed 
by the UMass Mouse Phenotyping Core Facility using the cytokine mouse 
23-plex Bio-Plex kit (Bio-Rad) and Bio-Plex 200 Luminex machine. For analy-
sis of CCR1 by ELISA, kidneys were taken from mice between 3 and 7 days 
after infection, snap frozen, and stored at –80°C until further processing. 
Kidneys were then thawed on ice, resuspended in PBS, homogenized using 
a Tissuemiser (Fisher Scientific), and centrifuged at 4°C. The supernatant 
was assayed via ELISA (Chemokine C-C-Motif Receptor 1 [CCR1] ELISA, 
Antibodies-Online.com) according to the manufacturer’s protocols.
and HindIII. C. rodentium tir — cesT was then amplified using F-MluI-Cr-
tirU and R-SacII-Cr-tirL and ligated into MluI and SacII site of pEM123 to 
create pEM129. Sequencing was performed at the DNA Sequencing Core 
Facility at Tufts Medical School.
ELISA quantification of Stx. Overnight bacterial cultures with antibiotic 
were diluted into a 5-ml culture with new medium and antibiotic. The cul-
tures were grown to an OD600 of 0.5–0.7. Mitomycin C (5 μl of 0.5 ng/ml) 
was added to cultures, and they were grown overnight with agitation. Cul-
tures were spun at 17,800 × g for 5 minutes at room temperature. Superna-
tants were collected for analysis. To prepare pellets for ELISA, pellets were 
washed with 1 M Tris pH 8 on ice, frozen at –70°C for 30 minutes, resus-
pended in 1 ml ice-cold 1 M Tris pH 8, and sonicated (20-second bursts, 3 
times) and prepared for Stx2 ELISAs. 96-well plates (Corning MaxiSorp) 
were coated with 4D1 Stx2 antibody (a gift from Cheleste Thorpe, Tufts 
University) at 1:1,000 in coating buffer, pH 9.6, overnight at 4°C. The 
plate was then blocked with 2% BSA in PBS or coating buffer for 1 hour at 
room temperature. Plates were washed 5 times with PBS/Tween 20 (0.05%). 
Samples of bacterial supernatants or lysed pellets were added to wells, then 
incubated 1 hour at room temperature. The primary antibody, rabbit anti-
Stx2 203αCT69 (a gift from Cheleste Thorpe), was added to the wells for 
30 minutes, followed by secondary antibody, anti-rabbit IgG Fc AP conju-
gate (Promega), for 30 minutes. Freshly prepared para-nitrophenyl phos-
phate (Sigma-Aldrich) was used as substrate. ODs were read at 405 nm.
Mucus activation assays. Activation assays were performed as previously 
described (46, 58). Briefly, culture supernatants, were incubated with intes-
tinal mucus from the small intestine of a mouse at a final concentration of 
1 mg/ml for 2 hours at 37°C. As a control, a separate sample of each prepa-
ration was treated with HEPES buffer and incubated in the same manner. 
Following incubation with mucus or HEPES, protease inhibitor was added 
and samples were frozen at –20°C until ready to assay. The cytotoxicity of 
the samples was then determined on Vero cells (as described in refs. 46, 58). 
The level of activation was determined by dividing the cytotoxicity of the 
mucus-treated sample by the cytotoxicity of the HEPES-treated sample. 
Data shown are the average ± SEM of at least 2 activation assays.
Analysis of pedestal formation by C. rodentium on cultured cells. Filamentous actin 
staining (FAS) assays using C. rodentium were done as previously described 
(119). Briefly, a single colony from each strain was grown in 1 ml medium 
(with or without antibiotic) for 8 hours. Cultures were diluted 1:500 into 5 ml 
DMEM supplemented with 0.1 M HEPES (pH 7.0) (with or without antibi-
otic) and incubated at 37°C without agitation with 5% CO2 for 12–15 hours. 
Cell monolayers were prepared by splitting 95%–100% confluent MEFs into 
24-well culture plates containing sterile glass coverslips, followed by overnight 
growth at 37°C with 5% CO2. Prior to seeding onto culture plates, MEFs were 
maintained in MEF cell culture medium (DMEM [high glucose] plus 10% 
FBS with penicillin, streptomycin, and glutamine) at 37°C, 5% CO2. For infec-
tions, cell monolayers were washed twice with sterile PBS, followed by addi-
tion of FAS medium containing 25 μl overnight-cultured C. rodentium to each 
well. Plates were spun at 700 g for 10 minutes, then incubated at 37°C with 5% 
CO2 for 3 hours. After 1.5 hours, plates were spun again at 700 g for an addi-
tional 10 minutes to insure proper bacterial binding to cells. After 3 hours, 
cells were washed twice with sterile PBS, and 0.5 ml prewarmed FAS medium 
was added to each well, followed by an additional 3 hours incubation. Cells 
were washed 5 times with sterile PBS, fixed with 4% PFA for 30 minutes, 
washed, permeabilized with 0.1% Triton X-100, and then stained with phal-
loidin (Molecular Probes, Invitrogen) (1:100) and DAPI (1:500). After cells 
were washed an additional 3 times with PBS, the coverslips were mounted on 
slides using ProLong Gold antifade reagent (Invitrogen).
Mouse infections. Mice were purchased from the Jackson Laboratory and 
housed in the University of Massachusetts Medical School (UMass) animal 
facility. Female 3- to 8-week old C57BL/6J mice were gavaged with PBS or 
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ples were then rinsed twice in the same fixation buffer and post-fixed 
with 1% osmium tetroxide for 1 hour at room temperature. Samples 
were then washed twice with DH2O for 20 minutes at 4°C and then 
dehydrated through a graded ethanol series of 20% increments, before 
2 changes in 100% ethanol. Subsequently, samples were infiltrated first 
with 2 changes of 100% propylene oxide and then with a 1:1 mix of pro-
pylene oxide/SPI-Pon 812 resin. The following day, 3 changes of fresh 
100% SPI-Pon 812 resin were done before the samples were polymer-
ized at 68°C in plastic capsules. The samples were then reoriented, and 
thin sections were placed on copper support grids and stained with lead 
citrate and uranyl acetate. Sections were examined using the FEI Tecani 
12 BT with 80-kV accelerating voltage, and images were captured using 
a Gatan TEM CCD camera.
Statistics. Data were analyzed using GraphPad Prism software. Compari-
son of multiple groups was performed using 1-way ANOVA with Tukey’s 
multiple comparison post-tests or 2-way ANOVA with Bonferroni’s post-
tests. Statistical significance of differences between 2 groups was evaluated 
using 2-tailed unpaired t tests. In all tests, P values below 0.05 were consid-
ered statistically significant. In all graphs, data represent the mean ± SEM, 
unless otherwise indicated.
Nucleotide sequence and accession numbers. stxA (Stx2d activatable A subunit) 
from Phage 1720a02: BankIt1463613 Seq1 JN194203. stxB (Stx2d activat-
able B subunit) from Phage 1720a02: BankIt1463613 Seq2 JN194204.
Study approval. All animal studies were approved by the UMass Depart-
ment of Animal Medicine and IACUC (protocol 2049).
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Bb, sC5b-9, C3, and D-dimer ELISAs. For Bb, sC5b-9, and C3 analyses, blood 
was drawn via cardiac bleed at 6–8 days after infection from mock-infected 
mice or mice infected with the designated C. rodentium strain. Blood was 
allowed to clot for 30 minutes at room temperature and was then spun 
at 10,000 g for 15 minutes at 4°C, and serum was collected. Serum was 
spun at 10,000 g for an additional 15 minutes at 4°C, and the remaining 
serum was collected and frozen at –80°C until analysis. Mouse factor B 
(BF, Bb) ELISA Kit (TSZ ELISA) was used according to the manufacturer’s 
protocols to measure serum Bb. Mouse sC5b-9 was measured using the 
mouse terminal complement complex C5b-9 (TCC C5b-9) ELISA Kit (TSZ 
ELISA) according to manufacturer’s protocols. Concentrations of serum 
C3 were determined using a Mouse C3 ELISA Kit (GenWay) according to 
the manufacturer’s protocols. To measure levels of D-dimer in the blood, 
whole blood was taken from mice via cardiac bleed at 4 time points based 
on colonization level (1: 107 CFU/g feces; 2: 108 CFU/g feces; 3: 109 CFU/g 
feces; and 4: prior to euthanasia [after a mouse had lost >15% body weight]) 
and collected into a tube containing trisodium citrate anticoagulant (at 
a concentration of 9:1 blood/anticoagulant). Blood was centrifuged for 
10 minutes at 2,500 g, and plasma was isolated and stored at –20°C until 
analysis. ELISA was performed using a Mouse D-Dimer (D2D) ELISA kit 
(K-Assay, Kamiya Biomedical Co.).
Serum chemistry and cytokine analysis. Blood was collected via cardiac 
puncture at necropsy and allowed to clot on ice for 30 minutes. Blood 
was spun at 10,000 g for 15 minutes at 4°C, and serum was collected. 
Serum was spun at 10,000 g for an additional 15 minutes at 4°C, and 
the remaining serum was collected and frozen at –80°C until analysis. 
The UMass Mouse Phenotyping Core Facility determined serum BUN 
and creatinine using a Cobas analyzer and serum cytokine concentrations 
using a mouse 23-plex Bio-plex kit (Bio-Rad) with a Bioplex 200 Luminex 
analyzer. Additional serum chemistry tests including the comprehensive 
metabolic profile (i.e., electrolytes, creatinine, BUN, AST, globulin, ALT, 
total protein, alkaline phosphatase, CPK, and albumin) were performed 
at IDEXX laboratories (North Grafton).
Complete blood cell count analysis. For complete blood count and hemato-
logical analysis, at 3–7 days after infection 500 μl murine whole blood was 
collected by cardiac puncture into an EDTA-containing Eppendorf tube 
and mixed thoroughly. Tests were performed at the UMass Animal Facility 
Laboratory and at IDEXX Laboratories. Red blood cell and platelet counts 
were also measured daily for up to 10 days after infection by flow cytom-
etry in mock-infected mice and mice infected with C. rodentium (λstx2dact) as 
previously described (121, 122).
TEM. Mouse intestinal tissue samples were taken at various time 
points after infection and fixed in 2.5% gluteraldehyde in 0.05 M sodium 
phosphate buffer, pH 7.2. Samples were processed and analyzed at the 
UMass Electron Microscopy core facility according to standard proce-
dures. Briefly, fixed samples were moved into fresh 2.5% gluteraldehyde 
in 0.05 M sodium phosphate buffer and left overnight at 4°C. The sam-
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